192 related articles for article (PubMed ID: 27525651)
1. Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis.
Billeskov R; Tan EV; Cang M; Abalos RM; Burgos J; Pedersen BV; Christensen D; Agger EM; Andersen P
PLoS One; 2016; 11(8):e0161217. PubMed ID: 27525651
[TBL] [Abstract][Full Text] [Related]
2. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection.
Lin PL; Dietrich J; Tan E; Abalos RM; Burgos J; Bigbee C; Bigbee M; Milk L; Gideon HP; Rodgers M; Cochran C; Guinn KM; Sherman DR; Klein E; Janssen C; Flynn JL; Andersen P
J Clin Invest; 2012 Jan; 122(1):303-14. PubMed ID: 22133873
[TBL] [Abstract][Full Text] [Related]
3. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
4. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
[TBL] [Abstract][Full Text] [Related]
5. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
6. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule.
Luo Y; Jiang W; Da Z; Wang B; Hu L; Zhang Y; An R; Yu H; Sun H; Tang K; Tang Z; Wang Y; Jing T; Zhu B
Scand J Immunol; 2012 Mar; 75(3):293-300. PubMed ID: 22117839
[TBL] [Abstract][Full Text] [Related]
7. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
8. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis.
Haile M; Schröder U; Hamasur B; Pawlowski A; Jaxmar T; Källenius G; Svenson SB
Vaccine; 2004 Mar; 22(11-12):1498-508. PubMed ID: 15063575
[TBL] [Abstract][Full Text] [Related]
9. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
[TBL] [Abstract][Full Text] [Related]
10. Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.
Ciabattini A; Pettini E; Fiorino F; Lucchesi S; Pastore G; Brunetti J; Santoro F; Andersen P; Bracci L; Pozzi G; Medaglini D
Front Immunol; 2018; 9():380. PubMed ID: 29593710
[TBL] [Abstract][Full Text] [Related]
11. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis vaccines: Opportunities and challenges.
Zhu B; Dockrell HM; Ottenhoff THM; Evans TG; Zhang Y
Respirology; 2018 Apr; 23(4):359-368. PubMed ID: 29341430
[TBL] [Abstract][Full Text] [Related]
13. Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.
Thakur A; Rodríguez-Rodríguez C; Saatchi K; Rose F; Esposito T; Nosrati Z; Andersen P; Christensen D; Häfeli UO; Foged C
Front Immunol; 2018; 9():2825. PubMed ID: 30555488
[TBL] [Abstract][Full Text] [Related]
14. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
15. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
16. Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes.
Joslyn LR; Pienaar E; DiFazio RM; Suliman S; Kagina BM; Flynn JL; Scriba TJ; Linderman JJ; Kirschner DE
Front Microbiol; 2018; 9():1734. PubMed ID: 30177914
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
[TBL] [Abstract][Full Text] [Related]
18. Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.
Hovav AH; Fishman Y; Bercovier H
Infect Immun; 2005 Jan; 73(1):250-7. PubMed ID: 15618161
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
